

NADPH Oxidase 4 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/NC67B9F6D5AFEN.html>

Date: December 2019

Pages: 65

Price: US\$ 3,500.00 (Single User License)

ID: NC67B9F6D5AFEN

Abstracts

NADPH Oxidase 4 - Pipeline Review, H2 2019

SUMMARY

According to the recently published report 'NADPH Oxidase 4 - Pipeline Review, H2 2019'; NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) pipeline Target constitutes close to 6 molecules.

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - NADPH oxidase 4 is an enzyme belonging to NOX family of NADPH oxidases. NADPH Oxidase 4 is localized to non-phagocytic cells where it acts as an oxygen sensor and catalyzes the reduction of molecular oxygen to various reactive oxygen species. So formed ROS have been implicated in numerous biological functions including signal transduction, cell differentiation and tumor cell growth.

The report 'NADPH Oxidase 4 - Pipeline Review, H2 2019' outlays comprehensive information on the NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II,

Phase I and Preclinical stages are 1, 1 and 4 respectively. Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Respiratory, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Musculoskeletal Disorders, Oncology and Toxicology which include indications Idiopathic Pulmonary Fibrosis, Acute Ischemic Stroke, Atherosclerosis, Chlorine Poisoning, Diabetic Complications, Diabetic Nephropathy, Fibrosis, Gastrointestinal Radiation Toxicity, Ischemia Reperfusion Injury, Kidney Fibrosis, Liver Fibrosis, Mustard Gas (Sulfur Mustard) Poisoning, Nerve Gas Poisoning, Non-Alcoholic Steatohepatitis (NASH), Portal Hypertension, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Progressive Supranuclear Palsy, Prostate Cancer, Pulmonary Radiation Toxicity, Systemic Sclerosis (Scleroderma) and Type 2 Diabetes.

SCOPE

The report provides a snapshot of the global therapeutic landscape for NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.)

The report reviews NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics and enlists all their major and minor projects

The report assesses NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics based on mechanism of action (MoA), route of

administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Overview

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Companies

Involved in Therapeutics Development

GenKyoTex SA

Glucox Biotech AB

New Amsterdam Sciences Inc

OliPass Corporation

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Drug Profiles

Antisense Oligonucleotides to Inhibit NOX4 for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAS-150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setanaxib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NOX-4 for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NOX4 and NOX2 for Ischemia Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Dormant Products

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Discontinued Products

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Product Development Milestones

Featured News & Press Releases

Dec 03, 2019: Genkyotex reports progress of Setanaxib Phase 2 investigator initiated trials

Jul 25, 2019: Genkyotex announces positive post-hoc analysis of PBC phase 2 trial and reports cash position at June 30, 2019

Jul 24, 2019: Genkyotex conference call for post-hoc analysis of Setanaxib (GKT831) PBC Ph2 trial and business update

Jul 22, 2019: The WHO recognizes NOX inhibitors as new therapeutic class and approves setanaxib for GKT831

Jul 18, 2019: Genkyotex to launch Phase II pulmonary fibrosis trial in US

Jul 01, 2019: Genkyotex's GKT831 prevents multiple complications of portal hypertension in preclinical model

Jun 24, 2019: Genkyotex announces positive final results of GKT831 trial in PBC

May 23, 2019: Genkyotex invites shareholders to Annual General Meeting on June 13, 2019

May 21, 2019: Preclinical study of GKT831 shows rapid regression of cholestatic fibrosis in model of advanced liver fibrosis

May 02, 2019: Genkyotex reports mixed efficacy Phase II data for PBC drug
Apr 08, 2019: Genkyotex to present updated interim results from Phase 2 trial of GKT831 in Primary Biliary Cholangitis at 2019 EASL International Liver Congress (ILC)
Mar 11, 2019: Genkyotex announces completion of 24-week treatment period of its phase 2 trial with GKT831 in primary biliary cholangitis
Feb 11, 2019: Genkyotex Announces Award of Grant from Cancer Research UK to Academic Partner to Further Develop NOX Research in Oncology
Jan 25, 2019: Genkyotex provides update on its primary biliary cholangitis drug candidate GKT831
Dec 19, 2018: Genkyotex announces an extraordinary shareholders meeting to be held on January 24, 2019 at 10 am and confirms the key development milestone for GKT831 in PBC

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by GenKyoTex SA, H2 2019
Pipeline by Glucox Biotech AB, H2 2019
Pipeline by New Amsterdam Sciences Inc, H2 2019
Pipeline by OliPass Corporation, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

GenKyoTex SA

Glucox Biotech AB

New Amsterdam Sciences Inc

OliPass Corporation

I would like to order

Product name: NADPH Oxidase 4 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/NC67B9F6D5AFEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NC67B9F6D5AFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970